NAC clinical brief
NAC
Dossier liveAHepatic
Evidence strength
High confidence
360 meta-analyses - 400 RCTs - 925 tracked studies
What it is for
General antioxidant / glutathione support
The clearest current human use case based on dose, outcomes, and clinical coverage.
What moves
Highest-signal biomarkers
Human linked
HOMA-IR
Glycemic control
Decrease
Grade A
Fasting insulin
Glycemic control
Decrease
Grade A
HbA1c
Glycemic control
No Significant Effect
Grade B
Top caution
Drug interaction
Physical adsorption of NAC onto activated charcoal surface in GI tract reduces oral NAC absorption when administered within 1-2h of each other; charcoal-NAC binding reduces NAC bioavailability
Evidence index
91
Authored product-registry confidence score
Meta-analyses
360
Pooled human evidence
RCTs
400
Randomized clinical trials
Tracked studies
925
Studies currently mapped to this dossier
Executive summary
Immediate brief
NAC is a Hepatic with its clearest current use in General antioxidant / glutathione support.
High confidence human evidence supports the brief, anchored by 925 tracked studies, 360 meta-analyses, 400 RCTs and the most reliable movement in HOMA-IR, Fasting insulin, HbA1c.
Physical adsorption of NAC onto activated charcoal surface in GI tract reduces oral NAC absorption when administered within 1-2h of each other; charcoal-NAC binding reduces NAC bioavailability Physical adsorption of NAC onto activated charcoal surface in GI tract reduces oral NAC absorption when administered within 1-2h of each other; charcoal-NAC binding reduces NAC bioavailability Current consensus: NAC not recommended for CIN prevention when adequate IV hydration is provided
Anchor decision
General antioxidant / glutathione support
Best current human use case
Confidence
High confidence
360 meta-analyses - 400 RCTs - 925 tracked studies
Read next
Drug interaction
Pressure-test the lead caution before acting.
Reading guide
How to use this brief
1. Orient
Use the overview tab to understand mechanism, safety, scope, and where the current evidence still has blind spots.
2. Pressure-test
Move into evidence and biomarkers once the memo already makes sense, so the tables confirm or challenge the narrative rather than replace it.
3. Operationalize
Finish with dosing and PGx when the compound still looks useful and you are deciding whether it belongs in a real protocol.
Major warning
CPregnancy - first trimester, elective high-dose use
Overview
Clinical posture
Start with mechanism and safety, then move into scope, synergies, and the open questions that still matter before going deeper into tables.
Primary signal
Mechanism summary
Read this as the shortest defensible explanation for why the compound belongs in the conversation at all.
Co-primary
Safety summary
These are the reasons this compound can still break trust if the protocol fit is otherwise attractive.
Supporting context
Evidence scope
Read these caveats before assuming the effect sizes generalize cleanly across every population or use case.
Evidence scope
ReviewCurrent consensus: NAC not recommended for CIN prevention when adequate IV hydration is provided
Publication bias
ReviewEffect likely genuine in elevated-inflammation populations; generalizability to lower-risk Western populations unconfirmed
Evidence scope
ReviewClassic COPD meta-analyses were conducted with 600 mg/day.
Evidence scope
ReviewInitial Berk et al.
Synergies
Potential pairing logic is useful only when it adds a cleaner decision path, not when it becomes an excuse to stack indiscriminately.
NAC + clomiphene_citrate
NAC as clomiphene adjunct specifically - not tested as monotherapy equivalent.
NAC + lifestyle_intervention
Lifestyle intervention is foundational; NAC augments outcome.
NAC + iv_hydration_saline
Standard combination protocol in nephrology/cardiology for high-risk contrast procedures.
Research unknowns
These are the open questions that still keep the compound from reading like a closed case.